Davidc Fabrey News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aduhelm, newly approved by the Food and Drug Administration as a treatment for Alzheimer s disease, is mired in controversy because of inconclusive results and its high cost.

United statesUnited kingdomDavidc fabreyBrad wenstrupAdvisory committee for peripheralBiogen companyAmerican academy of neurologyBiogen company cambridgeDrug administrationControversial alzheimerAmerican academyAdvisory committeeCentral nervous system drugs